SecBot SecBot
8-K ·Filed Apr 15, 2026

PDSB

PDS Biotechnology Corp
BULLISH
Impact 8/10
Horizonweeks Processed7mo ago SEC0001140361-26-014693
8-K context-dependent: Items 8.01
Actionable Insight ▲ Bullish

The strong clinical data could lead to accelerated regulatory approval and commercialization. Traders should monitor for potential partnership announcements or licensing deals with larger pharmaceutical companies.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$1.36
T+0 close · Apr 15, 2026 · via day close
Latest settled
−43.10%
T+60 · $0.7739
Vs SPY
−51.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 15 $1.36entry
  2. T+1 · 7mo ago −5.88%α −6.14% · $1.28
  3. T+5 · 7mo ago −5.15%α −6.79% · $1.29
  4. T+20 · 6mo ago −19.12%α −25.16% · $1.10
  5. T+60 · 4mo ago −43.10%α −51.23% · $0.7739
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

PDS Biotechnology announced positive interim Phase 2 clinical trial data for its drug PDS01ADC in treating metastatic colorectal cancer, showing a 78% objective response rate and 85% 2-year survival rate compared to 35% in a parallel trial.

Key Facts

  • PDS01ADC showed 77.8% objective response rate (ORR) at 6 months vs 35% in parallel trial
  • 24-month survival rate was approximately 85% vs 40% in parallel trial
  • Data published in Journal of Clinical Oncology (JCO) Oncology Advances
  • Trial conducted in unresectable microsatellite stable (MSS) or mismatch repair-proficient p(MMR) colorectal liver metastases
  • PDS01ADC is a tumor-targeted immunocytokine designed to deliver Interleukin-12 (IL-12) directly to tumors

Financial Impact

Significant improvement in clinical outcomes with 77.8% ORR vs 35% in control group and 85% 2-year survival vs 40% in control group

clinical trial resultssurvival ratesresponse rates

Risk Factors

  • Phase 2 data is still preliminary and may not translate to Phase 3 success
  • Competitors in the colorectal cancer space could impact market potential
  • The company's small market cap ($59M) makes it vulnerable to volatility

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001140361-26-014693
Document: ef20070560_ex99-1.htm0001140361-26-014693
Document: 0001140361-26-014693-index-headers.html0001140361-26-014693
Document: 0001140361-26-014693-index.html0001140361-26-014693
Document: 0001140361-26-014693.txt0001140361-26-014693

Track record

28 reports on PDSB

Performance horizon

7 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +71.95% at T+20 after the Jul 22, 2026 report. 11 of 13 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Entry $0.8726 Now $0.9240 +5.89% settles Dec 14
  2. Nov 12, 20264d ago SC 13D/A Neutral 4/10 Entry $0.9800 Now $0.9240 −5.71% settles Dec 11
  3. Nov 10, 20266d ago 8-K Neutral 4/10 Entry $1.03 Now $0.9240 −10.29% settles Dec 9
  4. Oct 20, 202627d ago 3 Neutral 2/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  5. Oct 20, 202627d ago 8-K Neutral 4/10 Entry $1.24 Now $0.9240 −25.48% settles Nov 18
  6. Oct 20, 202627d ago 8-K Neutral 3/10 Entry $0.9605 Now $0.9240 −3.80% settles Nov 17
  7. Oct 14, 20264w ago S-3 Bearish 7/10 Entry $1.30 to $0.9800 Now $0.9240 +28.92% ▲ +24.62% +22.71% vs SPY
  8. Oct 6, 20265w ago 8-K Neutral 3/10 Entry $1.05 to $1.41 Now $0.9240 −11.58% ▲ +34.93% +38.10% vs SPY
  9. Sep 22, 20267w ago 8-K Bullish 6/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
  10. Sep 22, 20267w ago Press Release Bullish 7/10 Entry $0.9100 to $0.9605 Now $0.9240 +1.54% ▲ +5.55% +6.11% vs SPY
Showing 10 of 28

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 15, 2026